Navigation Links
MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
Date:12/20/2011

ROCKVILLE, Md., Dec. 20, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced today that it will receive a milestone payment from Boehringer Ingelheim.  The milestone payment was triggered as part of an agreement executed in October 2010 to discover, develop and commercialize antibody-based therapeutics based on MacroGenics' Dual-Affinity Re-Targeting (DART) platform.  The amount of the milestone payment remained undisclosed.  Therapeutics in the global alliance will be directed against up to ten combinations of molecular targets and may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases.  To date, MacroGenics has achieved five pre-clinical milestones across both of its DART collaborations with Boehringer Ingelheim and Pfizer, Inc.

Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics, commented: "We are very encouraged by the progress we've made with this DART candidate in collaboration with Boehringer Ingelheim."  Dr. Koenig continued, "MacroGenics expects to advance multiple product candidates from this alliance in 2012 and beyond."

About MacroGenics
MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) bispecific technology, which allows the incorporation of multiple specificities within a single recombina
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
2. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
3. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. Paulo F. Costa Joins MacroGenics Board of Directors
6. MacroGenics Appoints New Vice President of Business Development
7. MacroGenics Raises $25M in Series D-2 Financing
8. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
9. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
10. Watsons Generic Yaz(R) Receives FDA Approval
11. UCSB professor receives award for graphene electronics research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... more than EUR 1.022 billion in 2013; while production volume reached close to ... leading producing country with a share of 75.5% of the region’s total aluminium ...
(Date:7/28/2015)... -- Deerfield Management Company, L.P. today announced the launch ... invest in groundbreaking advancements in science that may lead ... diseases. The venture capital fund will also back new ... improve the way healthcare is delivered to patients. ... funds in the sector, will donate all profits not ...
(Date:7/28/2015)... July 28, 2015 BioStructures, LLC, a ... hit a milestone of 4,000 implantations of Signafuse® ... cleared in early 2014 as a bone void ... fusion procedures.  This is a distinguished status among ... 6% of new synthetic products have received clearance ...
(Date:7/28/2015)... ZIONA, Israel , July ... (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its ... today announced that Shomrat Shurtz has been appointed ... 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... 25 years of experience in marketing, regulatory and ...
Breaking Biology Technology:EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Revolutionary Bone Graft Exceeds Expectations 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2
... , , - ... - , TORONTO and EDMONTON, Dec. 17 /PRNewswire-FirstCall/ - Spectral ... today announced that BioMS Medical ("BioMS") and a syndicate of ... the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, ...
... Wash. Six scientists from the Department of ... fellows of the American Association for the Advancement ... science or its applications. The PNNL honorees ... Scott Chambers, physics; Moe Khaleel, engineering; Yuehe Lin, ...
... ... that a new market research report is available in ... Testing , http://www.reportlinker.com/p0170008/Infectious-Disease-Molecular-Diagnostic-Testing.html ... clinical significance and market needs for major infectious diseases, ...
Cached Biology Technology:Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis 2Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis 3Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis 4Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis 5Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis 66 PNNL scientists elected AAAS fellows 26 PNNL scientists elected AAAS fellows 3Reportlinker Adds Infectious Disease Molecular Diagnostic Testing 2
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... diarrhea cases among U.S. travelers to Mexico and ... of nonbacterial gastroenteritis outbreaks usually associated with developed ... at the Johns Hopkins Bloomberg School of Public ... that the longer travelers stayed at their destination, ...
... by researchers at the Department of Human Evolution, Max ... Washington University in St. Louis, has extracted and sequenced ... to approximately 75,000 years old. , This is the ... be published the week of March 7-11 in the ...
... large, randomized clinical trial for patients with previously ... has spread from the breast to other parts ... received bevacizumab (Avastin? in combination with standard chemotherapy ... progressed than patients who received the same chemotherapy ...
Cached Biology News:Norovirus found to cause traveler's diarrhea 2Oldest fossil human protein ever sequenced 2Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer 2Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer 3
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... Anti-acetyl-Histone H3 (Lys 4) ... sequence ...RT[ Ac K]Q... in which [ ... of human histone H3 ... Molecular Weight: Mr ~17kDa ...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
b-Catenin (pSer675), phospho-specific...
Biology Products: